Publications by authors named "Martin Dreyling"

100Publications

EHA Endorsement of ESMO Clinical Practice Guidelines for Newly Diagnosed and Relapsed Mantle Cell Lymphoma.

Hemasphere 2020 Oct 17;4(5):e464. Epub 2020 Aug 17.

Department of Medicine III, LMU Hospital, Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/HS9.0000000000000464DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437561PMC
October 2020

Mantle cell lymphoma.

Crit Rev Oncol Hematol 2020 Sep 4;153:103038. Epub 2020 Jul 4.

Medizinische Klinik III der Universität München-Grosshadern, München, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2020.103038DOI Listing
September 2020

EHA Endorsement of ESMO Clinical Practice Guidelines for Marginal Zone Lymphomas.

Hemasphere 2020 Apr 11;4(2):e351. Epub 2020 Mar 11.

Department of Medicine III, University Hospital, LMU, Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/HS9.0000000000000351DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7162085PMC
April 2020

New Treatment Options in Advanced Stage Follicular Lymphoma.

Hemasphere 2018 Dec 28;2(6):e156. Epub 2018 Nov 28.

University Hospital, LMU Munich, Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/HS9.0000000000000156DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745966PMC
December 2018

Are Biosimilars the Future of Oncology and Haematology?

Drugs 2019 Oct;79(15):1609-1624

Department of Oncology and Hemato-Oncology, University of Milano, Milano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-019-01193-yDOI Listing
October 2019

Mantle cell lymphoma: therapeutic options in transplant-ineligible patients.

Leuk Lymphoma 2019 11 25;60(11):2622-2634. Epub 2019 Apr 25.

Department of Medicine III, University Hospital Ludwig Maximilians University, Munich, Germany.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/10428194.2019.1
Publisher Site
http://dx.doi.org/10.1080/10428194.2019.1605511DOI Listing
November 2019

Recent advances and future directions in mantle cell lymphoma research: report of the 2018 mantle cell lymphoma consortium workshop.

Leuk Lymphoma 2019 08 30;60(8):1853-1865. Epub 2019 Jan 30.

f GW Cancer Center, George Washington University , Washington , DC , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1571205DOI Listing
August 2019

Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge!

Blood 2018 12 1;132(26):2722-2729. Epub 2018 Nov 1.

Department of Haematology, Derriford Hospital, Plymouth, United Kingdom.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/lookup/doi/10.1182/blood-2017-08
Publisher Site
http://dx.doi.org/10.1182/blood-2017-08-737502DOI Listing
December 2018

The Diagnosis and Treatment of Primary CNS Lymphoma.

Dtsch Arztebl Int 2018 06;115(25):419-426

Department of Neurology, Medical Center of the University of Munich (LMU), Munich; Department of Hematology, Oncology and Palliative Care, Stuttgart Cancer Center/Tumor Center Eva-Mayr-Stih, Klinikum Stuttgart; Medical Department, Division of Oncology and Hematology, Charité - Universitätsmedizin Berlin; Department of Neurology, University Hospital Knappschaftskrankenhaus Bochum; Department of Neuropathology, University Hospital Cologne; Department of Internal Medicine III, Hospital of the University of Munich (LMU).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3238/arztebl.2018.0419DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056710PMC
June 2018

Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials.

Leuk Lymphoma 2018 12 18;59(12):2769-2781. Epub 2018 Jun 18.

b Sir Peter MacCallum Department of Oncology , University of Melbourne , Melbourne , Victoria , Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2018.1457148DOI Listing
December 2018

A closer look at copanlisib.

Authors:
Martin Dreyling

Clin Adv Hematol Oncol 2018 Jan;16(1):35-37

University Hospital, LMU Munich, Munich, Germany.

View Article

Download full-text PDF

Source
January 2018

Transient antagonism of anti-CD20 monoclonal antibodies and PI3K inhibitor idelalisib in DLBCL cell lines.

Eur J Haematol 2018 Apr 4. Epub 2018 Apr 4.

Department of Medicine III, Ludwig-Maximilians-University, Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13075DOI Listing
April 2018

Autologous Stem Cell Transplantation for Patients with Early Progression of Follicular Lymphoma: A Follow-Up Study of 2 Randomized Trials from the German Low Grade Lymphoma Study Group.

Biol Blood Marrow Transplant 2018 06 29;24(6):1172-1179. Epub 2018 Mar 29.

Department of Internal Medicine III, University Hospital of the Ludwig-Maximilians-University, Munich, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany; German Cancer Research Centre (DKFZ), Heidelberg, Germany. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.03.022DOI Listing
June 2018

Structured reporting adds clinical value in primary CT staging of diffuse large B-cell lymphoma.

Eur Radiol 2018 Sep 29;28(9):3702-3709. Epub 2018 Mar 29.

Institute of Diagnostic and Interventional Radiology, Technical University of Munich (TUM), Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00330-018-5340-3DOI Listing
September 2018

Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.

N Engl J Med 2018 03;378(13):1211-1223

From the Peter MacCallum Cancer Centre, Melbourne, VIC (C.S.T., M.A.A., R.A., S.H., R.J.H., K.B., G.T., J.D.I., M.B., D.W., S.L., S.-J.D., M.A.D., J.F.S., A.W.R.), and the Victorian Comprehensive Cancer Centre (C.S.T., M.A.A., R.A., S.H., R.J.H., K.B., D.W., S.-J.D., M.A.D., J.F.S., A.W.R.), the Faculty of Medicine (C.S.T., R.J.H., S.-J.D., M.A.D., J.F.S., A.W.R.) and Centre for Cancer Research (S.-J.D., M.A.D.), University of Melbourne, the Department of Clinical Haematology and Bone Marrow Transplantation, the Royal Melbourne Hospital (C.S.T., M.A.A., K.B., J.F.S., A.W.R.), and the Division of Cancer and Haematology, Walter and Eliza Hall Institute of Medical Research (M.A.A., A.W.R.), Parkville, VIC - all in Australia; and the University Hospital of Schleswig-Holstein, Kiel (C.P.), and Klinikum der Universität, Ludwig-Maximilian University of Munich, Munich (M.D.) - both in Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1715519DOI Listing
March 2018

[Malignant B-Cell Lymphoma: Advances in the Therapy of Follicular Lymphoma and Mantle-cell Lymphoma].

Dtsch Med Wochenschr 2018 01 9;143(1):46-51. Epub 2018 Jan 9.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0043-124004DOI Listing
January 2018

The role of B cell antigen receptors in mantle cell lymphoma.

J Hematol Oncol 2017 10 17;10(1):164. Epub 2017 Oct 17.

Department of Oncology and Hematology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13045-017-0533-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5646121PMC
October 2017

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.

J Clin Oncol 2017 Dec 4;35(35):3898-3905. Epub 2017 Oct 4.

Martin Dreyling, Ludwig Maximilians University of Munich, Munich; Georg Lenz, University Hospital Münster, Münster; Marius Giurescu, Karl Köchert, Henrik Seidel, and Florian Hiemeyer, Bayer AG, Berlin, Germany; Armando Santoro, Humanitas Clinical and Research Center, Rozzano; Pier Luigi Zinzani, University of Bologna, Bologna, Italy; Luigina Mollica, Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada; Sirpa Leppä, Helsinki University Central Hospital Cancer Center, Helsinki, Finland; George A. Follows, Addenbrooke's Hospital, Cambridge, United Kingdom; Won Seog Kim, Samsung Medical Center, Seoul, South Korea; Arnon Nagler, Tel Aviv University, Tel HaShomer, Israel; Panayiotis Panayiotidis, National and Kapodistrian University of Athens, Athens, Greece; Judit Demeter, Semmelweis University, Budapest, Hungary; Muhit Özcan, Ankara University School of Medicine, Ankara, Turkey; Marina Kosinova, Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation; Krimo Bouabdallah, University Hospital of Bordeaux, Pessac; Franck Morschhauser, Hôpital Claude Huriez, Lille, France; Don A. Stevens, Norton Cancer Institute, Louisville, KY; David Trevarthen, Comprehensive Cancer Care and Research Institute of Colorado, Englewood, CO; and Lisa Cupit, Li Liu, Carol Peña, Shuxin Yin, Jose Garcia-Vargas, and Barrett H. Childs, Bayer HealthCare Pharmaceuticals, Whippany, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.4648DOI Listing
December 2017

Combined therapy in MCL: less may be more?

Authors:
Martin Dreyling

Blood 2016 10;128(14):1782-1783

LUDWIG MAXIMILIANS UNIVERSITY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-07-726505DOI Listing
October 2016

Minimal residual disease in mantle cell lymphoma: are we ready for a personalized treatment approach?

Haematologica 2017 07;102(7):1133-1136

Department of Medicine III, Hospital of the University LMU München, Germany

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2017.167627DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5566011PMC
July 2017

Mantle cell lymphoma - Current standards of care and future directions.

Cancer Treat Rev 2017 Jul 13;58:51-60. Epub 2017 Jun 13.

Department of Medicine III, Hospital of the University LMU München, Germany. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2017.05.008DOI Listing
July 2017

Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphoma.

Neuro Oncol 2017 Nov;19(12):1618-1627

Institute of Clinical Neuroimmunology, Biomedical Center and Klinikum Grosshadern, Ludwig Maximilian University, Munich, Germany; Department of Neurology, Klinikum Grosshadern, Ludwig Maximilian University, Munich, Germany; Department of Medicine III, Klinikum Grosshadern, Ludwig Maximilian University, Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nox097DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5716176PMC
November 2017

Recent advances and future directions in mantle cell lymphoma research: report of the 2016 mantle cell lymphoma consortium workshop.

Leuk Lymphoma 2017 07 31;58(7):1561-1569. Epub 2017 Jan 31.

e Department of Medicine, George Washington University , Washington DC , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2017.1283036DOI Listing
July 2017

Recommendations for Clinical Trial Development in Mantle Cell Lymphoma.

J Natl Cancer Inst 2017 01 31;109(1). Epub 2016 Dec 31.

Affiliations of authors: Division of Hematology and Medical Oncology, Oregon Health and Science (OHSU) University Knight Cancer Institute, Portland, OR (SES); Clinical Research Division, Fred Hutchinson Cancer Research Center/ Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA (BGT, AKG); Department of Medicine, Weill Cornell Medicine, New York, NY (PM, JPL); John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ (AHG); Department of Medicine III, Klinikum der Universität München, Campus Grosshadern, Munich, Germany (MPD); Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA (ML); Wilmot Cancer Center and Division of Hematology/Oncology, University of Rochester, Rochester, NY (JWF); Coordinating Center for Clinical Trials, National Cancer Institute, National Institutes of Health, Bethesda, MD (LB); HIV and AIDS Malignancy Branch, Center for Cancer Research, and Clinical Investigations Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD (RFL); Department of Medicine, Oncology Division, Washington University, St. Louis, MO (BSK); Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH (MRS).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw263DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059122PMC
January 2017

Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.

J Clin Oncol 2017 Feb 19;35(5):536-543. Epub 2016 Dec 19.

Ralf U. Trappe and Heiner Zimmermann, DIAKO Evangelisches Diakonie-Krankenhaus Bremen, Bremen; University Medical Centre Schleswig-Holstein, Kiel; Ralf U. Trappe, Petra Reinke, Ioannis Anagnostopoulos, and Hanno Riess, Charité-Universitätsmedizin Berlin, Berlin; Martin H. Dreyling and Marion Subklewe, University of Munich, Munich; Ulrich Dührsen and Andreas Hüttmann, University of Duisburg-Essen, Essen; Volker Kliem, Nephrological Centre Lower Saxony, Hann. Münden; Ingeborg A. Hauser, J.W. Goethe University Hospital, Frankfurt, Germany; Daan Dierickx, Gregor Verhoef, Thomas Tousseyn, and Olivier Gheysens, Catholic University Leuven, Leuven; Eric Van Den Neste, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Franck Morschhauser, Hôpital Claude Huriez, Lille; Gilles Salles, Hospices Civils de Lyon and Université de Lyon, Pierre-Bénite; Veronique Leblond and Sylvain Choquet, Université Pierre et Marie Curie, Paris, France; Peter Mollee, University of Queensland, Brisbane, Queensland, Australia; Jan M. Zaucha, Medical University of Gdansk, Gdansk; Polish Lymphoma Research Group, Warsaw, Poland; and Corrado Tarella, European Institute of Oncology, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.3564DOI Listing
February 2017

Time to publish: challenging the performance of cooperative group lymphoma trials.

Lancet Haematol 2017 Jan 2;4(1):e8-e10. Epub 2016 Dec 2.

Medical Clinic III, Clinic of München University, Campus Grosshadern, München, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(16)30084-9DOI Listing
January 2017

Complementarity determining region-independent recognition of a superantigen by B-cell antigen receptors of mantle cell lymphoma.

Haematologica 2016 09;101(9):e378-81

Department of Oncology and Hematology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany Department of Hematology and Oncology, Augsburg Medical Center, Germany

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2016.141929DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5060035PMC
September 2016

The Emerging Role of PI3K Inhibitors in the Treatment of Hematological Malignancies: Preclinical Data and Clinical Progress to Date.

Drugs 2016 Apr;76(6):639-46

Department of Internal Medicine III, University Hospital Grosshadern, Ludwig Maximilians University (LMU), Marchioninistraße 15, Munich, 81377, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-016-0565-4DOI Listing
April 2016

Altered treatment of chronic lymphocytic leukemia in Germany during the last decade.

Ann Hematol 2016 May 29;95(6):853-61. Epub 2016 Mar 29.

Department of Internal Medicine III, University Hospital Munich-Großhadern, Marchioninistr. 15, 81377, Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-016-2640-zDOI Listing
May 2016

Phase II Trial of Temsirolimus for Relapsed/Refractory Primary CNS Lymphoma.

J Clin Oncol 2016 05 14;34(15):1757-63. Epub 2016 Mar 14.

Agnieszka Korfel, Antonio Pezzutto, Eckhard Thiel, and Philipp Kiewe, Charité University Medicine Berlin; Thomas Grobosch, Labor Berlin - Charité Vivantes, Berlin; Uwe Schlegel, Ruhr-Universität Bochum, Bochum; Ulrich Herrlinger and Sied Kebir, University Hospital Bonn, Bonn; Martin Dreyling, Christian Schmidt, and Luisa von Baumgarten, Hospital of the Ludwig Maximilian University München, Munich; and Peter Martus, University Tuebingen, Tuebingen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.9897DOI Listing
May 2016

Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.

J Clin Oncol 2016 Apr 29;34(12):1386-94. Epub 2016 Feb 29.

Eva Hoster, Roswitha Forstpointner, Christian Schmidt, Wolfgang Hiddemann, Michael Unterhalt, and Martin H. Dreyling, University Hospital Munich; Eva Hoster, University of Munich, Munich; Andreas Rosenwald, University of Würzburg, Würzburg; Heinz-Wolfram Bernd, University Hospital Schleswig-Holstein, Lübeck; Sylvia Hartmann, University Hospital of Frankfurt, Frankfurt am Main; Christoph Loddenkemper, University Hospital Berlin Charité; Christoph Loddenkemper, Pathologie PathoTres, Berlin; Thomas F.E. Barth, University Medical Center Ulm; Stephan Stilgenbauer, University of Ulm, Ulm; Michael Hallek, Universität zu Köln, Köln; Ursula Vehling-Kaiser, Tagesklinik Hämatologie Onkologie, Landshut; Lothar Kanz, University of Tübingen, Tübingen; Michael Pfreundschuh, Universitätsklinik des Saarlandes, Homburg; Wolfram Klapper, University of Kiel, Kiel, Germany; Françoise Berger, LYSA Group; Nicole Brousse, Hopital Necker; Catherine Thieblemont, Hôpital Saint Louis; Olivier Hermine, University Paris Descartes; Olivier Hermine, Université Sorbonne Paris Cité, Paris; Bertrand Coiffier, Centre Hospitalier Lyon-Sud, Pierre-Bénite; Réda Bouabdallah, Service d'Hématologie, Marseille; Vincent Ribrag, Institut Gustave Roussy, Villejuif, France; Stefano Pileri, University of Bologna, Bologna, Italy; Grzegorz Rymkiewicz, The Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; Roman Kodet, Charles University, Prague, Czech Republic; and Johanna C. Kluin-Nelemans, University of Groningen, Groningen, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.8387DOI Listing
April 2016

The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?

Haematologica 2016 Feb;101(2):104-14

Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2014.119115DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938333PMC
February 2016

Temsirolimus acts as additive with bendamustine in aggressive lymphoma.

Ann Hematol 2016 Feb 11;95(3):403-7. Epub 2015 Dec 11.

Department of Internal Medicine III, University Hospital Munich-Großhadern, Marchioninistr. 15, 81377, Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-015-2570-1DOI Listing
February 2016

The G protein-coupled estrogen receptor 1 (GPER-1) contributes to the proliferation and survival of mantle cell lymphoma cells.

Haematologica 2015 Nov 6;100(11):e458-61. Epub 2015 Aug 6.

Institute of Pathology, University of Würzburg and Comprehensive Cancer Center (CCC) Mainfranken, Stuttgart, Germany

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2015.127399DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4825299PMC
November 2015

Temsirolimus inhibits cell growth in combination with inhibitors of the B-cell receptor pathway.

Leuk Lymphoma 2015 3;56(12):3393-400. Epub 2015 Aug 3.

a Department of Internal Medicine III , University Hospital Munich-Großhadern , Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2015.1023720DOI Listing
September 2016

Personalized medicine in lymphoma: is it worthwhile? The mantle cell lymphoma experience.

Haematologica 2015 Jun;100(6):706-8

Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2015.127472DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450615PMC
June 2015

High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma.

Blood 2015 Jul 28;126(5):604-11. Epub 2015 May 28.

Department of Internal Medicine III, University Hospital Munich, Munich, Germany; Department of Medical Informatics, Biometry, and Epidemiology, University of Munich, Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-02-628792DOI Listing
July 2015

Haematological cancer: Bortezomib in MCL--new standard of care or just another option?

Authors:
Martin Dreyling

Nat Rev Clin Oncol 2015 Jul 26;12(7):376-8. Epub 2015 May 26.

Department of Medicine III, University Hospital, Ludwig-Maximilians University, Marchioninistrasse 15, 81377 Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2015.101DOI Listing
July 2015

Advances and issues in mantle cell lymphoma research: report of the 2014 Mantle Cell Lymphoma Consortium Workshop.

Leuk Lymphoma 2015 25;56(9):2505-11. Epub 2015 May 25.

e H. Lee Moffitt Cancer Center and Research Institute , Tampa , FL , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2015.1045903DOI Listing
August 2016

Bendamustine and the immune system: a wolf in sheep's clothing?

Leuk Lymphoma 2015 Apr;56(4):837-8

Department of Medicine III, Ludwig-Maximilians University of Munich , Munich , Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2015.1024942DOI Listing
April 2015

Everolimus maintenance in patients with mantle cell lymphoma not eligible for intensive therapy: results of a prematurely closed phase 2 study.

Leuk Lymphoma 2015 31;56(11):3227-9. Epub 2015 Mar 31.

a III. Medical Department, Technische Universität München , Munich , Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2015.1028055DOI Listing
September 2016

Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group.

J Clin Oncol 2014 Dec 17;32(36):4127-33. Epub 2014 Nov 17.

Michael Pfreundschuh, Viola Poeschel, Gerhard Held, Tanja Rixecker, Carsten Zwick, and Niels Murawski, Universitätsklinikum des Saarlandes, Homburg; Samira Zeynalova, Leipzig University, Leipzig; Mathias Hänel, Klinikum Chemnitz, Chemnitz; Norbert Schmitz, Asklepios Klinik St Georg, Hamburg; Andreas Viardot, Universitätsklinikum Ulm, Ulm; Martin H. Dreyling, Klinikum Großhadern; Ulrich Keller, Klinikum Rechts der Isar, Munich; Michael Hallek, Carsten Mueller, and Martin H.J. Wiesen, Universitätsklinik Köln, Köln; Mathias Witzens-Harig, Universitätsklinik Heidelberg, Heidelberg; and Lorenz Truemper, Universitätsklinikum Göttingen, Göttingen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.54.6861DOI Listing
December 2014

New paradigms in mantle cell lymphoma: is it time to risk-stratify treatment based on the proliferative signature?

Clin Cancer Res 2014 Oct;20(20):5194-206

Department of Pathology, Hematopathology Section and Lymph Node Registry Kiel. University Hospital Schleswig-Holstein, Campus Kiel, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-0836DOI Listing
October 2014